• Case Series: Click here to access the case series.

This feature was developed from a recorded webcast presented in PSAP 2023 Book 3 (Pulmonary and Gastrointestinal Diseases).

• Case Series: Click here to access the case series.

Author: Abigail M. Yancey, Pharm.D., FCCP, BCPS
Reviewed by: Patrick Finnegan, Pharm.D., BCPS; and Christian Hamm, Pharm.D., BCPS

Author: Chasity M. Shelton, Pharm.D., FCCP, BCPS, BCPPS
Reviewed by: Christopher M. Jones, Pharm.D., Dr.PH, MPH, BCPS, BCCP; and Brittany Florczykowski, Pharm.D., BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients with pulmonary and /or gastrointestinal diseases..

Learning Objectives

1. Evaluate patients for the etiology, pathophysiology, and risk factors associated with acute pancreatitis (AP) and chronic pancreatitis (CP).
2. Assess the severity of AP and CP in the clinical presentation (i.e., patient history, symptoms, laboratory values, and imaging) of a patient with AP and CP.
3. Develop an evidence-based, patient-specific plan for the treatment of AP and CP.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients with pulmonary and /or gastrointestinal diseases.

Learning Objectives

1. Classify the different types of electronic nicotine delivery systems (ENDS) and the additives used.
2. Account for regulations and laws associated with vaping products.
3. Assess the likelihood of e-cigarette, or vaping, product use-associated lung injury (EVALI) given the clinical presentation (i.e., patient history, symptoms, laboratory values, and imaging) of a patient with a history of vape use.
4. Develop a patient-specific treatment plan using available evidence for the treatment of EVALI and thrombotic complications.

Nothing to disclose: Patrick Finnegan, Christian Hamm, Abigail M. Yancey

Consultancies: Chasity Shelton (Wolters Kluwer, Lexi-Comp, Pediatric Pharmacy Association)
Grants: Chasity Shelton (UTHSC Diversity and Inclusion Mini-Grant, American Pharmacist's Association Foundation)
Other: Brittany Florczykowski (employment, Janssen Pharmaceuticals)
Nothing to disclose: Christopher M. Jones

Universal Activity Number: 0217-0000-24-192-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-24-193-H01-P
1.5 CPE contact hours
Application-Based Activity

Part I: Case Series: Pancreatitis
Part II: Recorded Webcast: Vaping
Includes online ACPE CPE/Recertification Credit posttests.
Posttest submission deadline for BCPS recertification credit is March 8, 2025.
Posttest submission deadline for ACPE CPE credit is September 8, 2027.

• Case Series: Click here to access the case series.

Authors: Melanie Smith Condeni, Pharm.D., BCPS, BCCCP
Reviewed by: Molly Droege, Pharm.D., BCPS; and Asmaa Kamal Mohammed, MSc, BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

1. Design a pain management plan for a patient in the surgical ICU (SICU).
2. Apply knowledge of shock types and markers of resuscitation to develop a postoperative resuscitation and hemodynamic management plan.
3. Develop a plan for the prevention of common SICU complications.
4. Develop a plan for the management of hematologic disorders of bleeding and prevention of thromboembolism for a SICU patient.
5. Evaluate the anti-microbial regimen of a SICU patient for appropriateness with regard to site of infection, common pathogens, and duration of therapy.
6. Justify appropriate blood glucose goals and convert a continuous insulin infusion for the management of stress hyperglycemia to an appropriate basal-bolus regimen in a SICU patient.

Consultancies: Molly Droege (SaNotize Research and Development)
Honoraria: Melanie Smith Condeni (Society of Critical Care Medicine)
Nothing to disclose: Asmaa Kamal

Universal Activity Number: 0217-0000-24-071-H01-P
1.5 CPE contact hours
Application-Based Activity

Part I: Case Series: Perioperative Management of Patients in the ICU

Includes online ACPE CPE/Recertification Credit posttest.
Posttest submission deadline for BCPS recertification credit is December 8, 2024.
Posttest submission deadline for ACPE CPE credit is June 8, 2027.

This feature was developed from a chapter presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

• Case Series: Click here to access the case series.

This feature was developed from a chapter presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

• Case Series: Click here to access the case series.

Authors: Ryan Feldman, Pharm.D., BCPS, DABAT; and James Leonard, Pharm.D., DABAT
Reviewed by: Julianne Yeary, Pharm.D., BCCCP; and Monica Owen, Pharm.D., BCPS, BCCCP

Author: Zachary R. Smith, Pharm.D., FCCP, BCPS, BCCCP
Reviewed by: Craig B. Whitman, Pharm.D., FCCM, BCCCP; and Megan Kaiser, Pharm.D., BCPS, BCGP

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

1. Classify prescription drug overdose by patient presentations.
2. Evaluate the causative agents of a drug overdose based on history and clinical findings of presentation.
3. Develop a treatment paradigm that may be applied in all prescription drug overdoses.
4. Assess the relevance of each therapeutic target in drug overdose in a specific drug overdose scenario.
5. Devise a plan for treatment of anticholinergic, sodium channel blocker, tricyclic antidepressant, bupropion, digoxin, sulfonylurea, alpha-2 agonist, iron, valproic acid, clonidine, and salicylate overdose.
6. Justify the use of specific antidotes in overdose.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

1. Apply bedside clinical assessment tools to detect pain, agitation, and delirium in the critically ill patient.
2. Design an evidence-based pharmacotherapy regimen for agitation in the critically ill patient.
3. Evaluate pharmacologic approaches for prevention and management of ICU delirium.
4. Assess therapeutic approaches to improve sleep quality in critically ill patients.
5. Develop a population-based approach for agitation, delirium, and sleep disturbance management in the ICU.

Consultancies: Ryan Feldman (Department of Health Services); James Leonard (Westat)
Honoraria: Ryan Feldman (ASHP/ACCP) Nothing to disclose: Julianne Yeary, Monica Owen

Grants: Zachary R. Smith (Shields Health Solution)
Nothing to disclose: Craig B. Whitman, Megan Kaiser

Universal Activity Number: 0217-0000-24-013-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-24-014-H01-P
1.5 CPE contact hours
Application-Based Activity

Part I: Case Series: Acute Management of Prescription and Nonprescription Drug Overdoses
Part II: Case Series: Acute Agitation, Delirium, and Sleep Management
Includes online ACPE CPE/Recertification Credit posttests.
Posttest submission deadline for BCPS recertification credit is September 8, 2024.
Posttest submission deadline for ACPE CPE credit is March 8, 2027.

This feature was developed from an interactive case presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

• Interactive case: Click here to access the interactive case.

This feature was developed from an interactive case presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).

• Interactive case: Click here to access the interactive case.

Author: Emily J. Owen, Pharm.D., MS, BCPS, BCCCP
Reviewed by: Jenna Goetz, Pharm.D., BCPS, BCCCP; and Rizah Anwar Assadi, Pharm.D., BCPS

Author: Madeline Jane Foertsch, Pharm.D., BCCCP
Reviewed by: Matthew J. Campbell, Pharm.D., BCPS, BCCCP; and Andrea Boland, Pharm.D., BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

1. Classify antithrombotic agents according to labeled indication, mechanism of action, and pharmacokinetic properties.
2. Assess life-threatening bleeding events caused by antithrombotic agents for treatment.
3. Evaluate the risk-benefit of treatments for life-threatening bleeding in the setting of an antithrombotic agent.
4. Develop an appropriate drug-dose regimen for a patient with life-threatening bleeding associated with an antithrombotic agent.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Learning Objectives

1. Assess the pharmacologic properties and indication or pretreatment agents used in rapid sequence intubation (RSI).
2. Evaluate the pharmacologic properties of induction agents used in RSI.
3. Distinguish the pharmacologic properties of neuromuscular blocking agents used in RSI.
4. Design appropriate patient-specific RSI regimens, and incorporate patient disease state interactions into them.

Emily Owen: Consultancies (Mallinckrodt); Honoraria (Mallinckrodt)
Nothing to disclose: Rizah Anwar Assadi, Jenna Goetz

Matthew J. Campbell: Grants (Spero Therapeutics)
Andrea Boland: Consultancies (Arkansas Association of Hospital Pharmacists)
Nothing to disclose: Madeline Jane Foertsch

Universal Activity Number: 0217-0000-23-223-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-23-224-H01-P
1.5 CPE contact hours
Application-Based Activity

This feature was developed from a live program presented in October 2022 at the ACCP Global Conference in San Francisco.

• Recorded Webcast: Click here to access the Recorded webcast.
• PDF Transcript: Click here to access the PDF Transcript.

This feature was developed from an interactive case presented in PSAP 2023 Book 1 (Endocrinology and Nephrology).

• Interactive case: Click here to access the interactive case.

Presenters: Craig J. Beavers, Pharm.D., FCCP, FACC, FAHA, BCCP, BCPS-AQ Cardiology, CACP; Kelly M. Rudd, Pharm.D., FCCP, BCPS; and Stephanie Dwyer Kaluzna, Pharm.D., BCCP
Reviewed by: Stormi E. Gale, Pharm.D., BCPS, BCCP; Candace Bryant, Pharm.D., BCPS; and A. Joshua Roberts, Pharm.D., BCCP, BCPS, AACC

Authors: Ayesha M. Khan, Pharm.D., BCPS; and Gary D. Peksa, Pharm.D., MBA, BCPS
Reviewed by: Wendy St. Peter, Pharm.D.; and Bryn Lindley, Pharm.D., BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with one or more common cardiac conditions or disorders.

Learning Objectives

1. Distinguish the incidence, pathophysiology, risk factors, and clinical presentation associated with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
2. Examine the clinical efficacy and safety data associated with agents recommended for the treatment of HFpEF.
3. Develop a pharmacologic treatment plan for HFrEF and HFpEF that optimizes the use of guideline-directed medical therapy.
4. Distinguish the thrombotic pathophysiology of antiphospholipid syndrome (APS).
5. Evaluate available evidence pertaining to the use of anticoagulants in patients with APS.
6. Develop an appropriate guideline-driven pharmacotherapeutic treatment plan for a patient with APS.
7. Design an antithrombotic treatment plan for a patient undergoing coronary stenting.
8. Analyze recent literature surrounding modified regimens of dual antiplatelet therapy in patients with coronary artery disease and acute coronary syndromes.
9. Distinguish between the various antithrombotic treatment regimens indicated for patients undergoing transcatheter aortic valve implantation.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with diabetes, CKD, or other specialized endocrinologic considerations.

Learning Objectives

1. Assess different methods in evaluating kidney function.
2. Develop patient care plans that equitably and safely address patients with kidney dysfunction.
3. Evaluate the influence of patient-specific factors on drug disposition.
4. Distinguish factors that must be considered when designing a drug dosing regimen for a patient with kidney impairment.

Nothing to disclose: Craig J. Beavers, Candace Bryant, Stormi E. Gale, Stephanie Dwyer Kaluzna, A. Joshua Roberts, Kelly M. Rudd

Consultancies: Wendy St. Peter (Glaxosmithkline)
Nothing to disclose: Ayesha M. Khan, Bryn Lindley, Gary D. Peksa

Universal Activity Number: 0217-0000-23-152-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-23-153-H01-P
1.5 CPE contact hours
Application-Based Activity

This feature was developed from an interactive case presented in PSAP 2023 Book 1 (Endocrinology and Nephrology).

• Interactive Case: Click here to access the interactive case.

This feature was developed from an interactive case presented in PSAP 2023 Book 1 (Endocrinology and Nephrology).

• Interactive case: Click here to access the interactive case.

Authors: Nicole E. Cieri-Hutcherson, Pharm.D., BCPS, NCMP; and Veronica Vernon, Pharm.D., BCPS, BCACP, NCMP
Reviewed by: Sarah M. Westberg, Pharm.D., FCCP, BCPS; and Abigail M. Yancey, Pharm.D., FCCP, BCPS

Author: Amy C. Donihi, Pharm.D., FCCP, BCPS, BC-ADM
Reviewed by: Krystal KC Riccio, Pharm.D., BCACP, CDCES; and Eman Elsayed Younis, Pharm.D., BCPS AQ-Cardiology

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with diabetes, CKD, or other specialized endocrinologic considerations.

Learning Objectives

1. Evaluate a patient for the appropriate use and initiation of menopausal hormone therapy (MHT).
2. Apply updates from guidelines and recent analyses of the Women’s Health Initiative data to the treatment of menopause and osteoporosis.
3. Develop appropriate nonpharmacologic and pharmacologic interventions for vasomotor symptoms of menopause and genitourinary syndrome of menopause.
4. Design a monitoring plan to assess the safety and effectiveness of pharmacotherapy for a patient using MHT.
5. Justify appropriate screening, diagnosis, and treatment of postmenopausal osteoporosis.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with diabetes, CKD, or other specialized endocrinologic considerations.

Learning Objectives

1. Develop a screening and treatment plan for a patient with or at risk of drug-induced endocrine abnormalities with checkpoint inhibitors.
2. Design a screening and treatment plan for a patient with or at risk of drug-induced thyroid disorders.
3. Devise a screening and treatment plan for a patient with or at risk of drug-induced osteoporosis.
4. Develop a screening and treatment plan for a patient with or at risk of drug-induced hyperglycemia.
5. Evaluate patients for possible drug interference with diagnostic endocrine laboratory tests.

Consultancies: Sarah M. Westberg (Minnesota Pharmacists Association)
Nothing to disclose: Nicole E. Cieri-Hutcherson, Veronica Vernon, Abigail M. Yancey

Nothing to disclose: Amy C. Donihi, Krystal KC Riccio, Eman Elsayed Younis

Universal Activity Number: 0217-0000-23-073-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-23-074-H04-P
1.5 CPE contact hours
Application-Based Activity

This feature was developed from an interactive case presented in PSAP 2022 Book 3 (Behavioral Health).

• Interactive Case: Click here to access the interactive case.

This feature was developed from an interactive case presented in PSAP 2022 Book 3 (Behavioral Health).

• Interactive case: Click here to access the interactive case.

Authors: Jonathan F. Lister, Pharm.D., BCPP; and Kara R. Wong, Pharm.D., BCPP
Reviewed by: Jacob T. Brown, Pharm.D., MS; Rizah Anwar Assadi, Pharm.D., BCPS; and Michelle Ganoff, Pharm.D., BCPS

Author: Jonathan G. Leung, Pharm.D., BCPS, BCPP
Reviewed by: Erica Davis, Pharm.D., BCPS, BCPP; Alisa Brown Chamblee, Pharm.D., BCPS; and Asmaa Kamal Mohammed, Pharm.D., BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists managing diverse patient populations.

Learning Objectives

1. Evaluate the evidence and guideline recommendations for pharmacogenomic (PGx) testing and therapeutic drug monitoring (TDM) in psychiatry.
2. Distinguish when a patient may benefit from PGx testing and TDM in psychiatry.
3. Assess psychiatric PGx and TDM results in a patient with mental illness.
4. Develop a treatment plan, including patient counseling, using PGx and/or TDM results for a patient with mental illness

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists managing diverse patient populations.

Learning Objectives

1. Develop a treatment plan involving clozapine using current evidence and clinical guidelines.
2. Assess patients for clinically relevant drug interactions with clozapine.
3. Justify the role of monitoring clozapine and norclozapine serum concentrations in clinical practice.
4. Account for potential clozapine-related adverse events during and after an acute hospital admission

Kara R. Wong: Consultancies (CPNP Recertification Editorial Board); Honoraria (College of Psychiatric and Neurologic Pharmacists)
Nothing to disclose: Rizah Anwar Assadi, Jacob T. Brown, Michelle Ganoff, Jonathan F. Lister

Jonathan G. Leung: Consultancies (Wolters-Kluwer)
Nothing to disclose: Erica Davis, Alisa Brown Chamblee, Asmaa Kamal Mohammed

Universal Activity Number: 0217-0000-23-009-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-23-010-H04-P
1.5 CPE contact hours
Application-Based Activity

This feature was developed from an interactive case presented in PSAP 2022 Book 2 (Current Issues in Pharmacotherapy).

• Interactive Case: Click here to access the interactive case.

This feature was developed from an interactive case presented in PSAP 2022 Book 2 (Current Issues in Pharmacotherapy).

• Interactive case: Click here to access the interactive case.

Author: Milena Murray, Pharm.D., FCCP, BCIDP, AAHIVP
Reviewed by: Joshua P. Vanderloo, Pharm.D., BCPS; and Marianne Billeter, Pharm.D., BCPS

Author: Matthew T. Stanton, Pharm.D., BCPS, DABAT
Reviewed by: Renee Petzel Gimbar, Pharm.D., FAACT; Megan E. Phillips, Pharm.D., BCPS, C-ELBW; and Samantha F. Geishauser, Pharm.D., BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists managing diverse patient populations.

Learning Objectives

1. Distinguish drug shortage causes on the basis of supply and demand.
2. Analyze patient care outcomes and risks because of drug shortages.
3. Design an appropriate management program for drug shortages.
4. Design an appropriate management program for drug shortages.
5. Resolve ethical issues related to drug shortages.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists managing diverse patient populations.

Learning Objectives

1. Justify the role of poison control centers in current and future toxicology practice.
2. Distinguish among the current treatments of acetaminophen toxicity.
3. Assess the role and place in therapy of physostigmine and rivastigmine for anticholinergic toxicity.
4. Evaluate a patient with methanol or ethylene glycol toxicity.
5. Design a therapeutic regimen for a patient with β-blocker or calcium channel blocker poisoning.

Milena M. Murray: Consultancies (VIIV; Theratechnologies); Honoraria (Merck)
Joshua Vanderloo: Consultancies (Quartz Insurance)
Nothing to disclose: Marianne Billeter

Renee Petzel Gimbar: Consultancies (Fresenius Kabi; ASHP); Grants (NIH; Xeris Pharmaceuticals)
Nothing to disclose: Samantha F. Geishauser, Megan E. Phillips, Matthew T. Stanton

Universal Activity Number: 0217-0000-22-247-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-22-248-H01-P
1.5 CPE contact hours
Application-Based Activity

This feature was developed from an interactive case presented in PSAP 2022 Book 1 (Cardiology).

• Interactive Case: Click here to access the interactive case.

This feature was developed from an interactive case presented in PSAP 2022 Book 1 (Cardiology).

• Interactive case: Click here to access the interactive case.

Authors: Glenn Herrington, Pharm.D., AACC, BCCP, BCPS, CDCES; and Daniel M. Riche, Pharm.D., FCCP, CLS, ASH-CHC
Reviewed by: Elisabeth M. Wang, Pharm.D., BCCP; Jessica Bente, Pharm.D., BCPS, BCGP; and Eman Elsayed Younis, Pharm.D., BCPS-AQ Cardiology

Author: Lindsey Federle, Pharm.D., BCCP, BCPS
Reviewed by: Jessie Dunne, Pharm.D., BCPS, BCCP; and Leslie Wooten, Pharm.D., BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering diverse cardiovascular patient populations.

Learning Objectives

1. Evaluate cardiovascular risk and complications to apply pharmacologic management strategies for hyperlipidemia in older adult patients.
2. Apply pharmacologic management strategies for hyperlipidemia in patients of various racial/ethnic backgrounds.
3. Apply pharmacologic management strategies for hyperlipidemia in patients with HIV infection.
4. Apply pharmacologic management strategies for familial hyperlipidemia.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering diverse cardiovascular patient populations.

Learning Objectives

1. Evaluate patient risk factors for cardiovascular complications during pregnancy and stratify according to the modified WHO pregnancy risk classes.
2. Distinguish the physiologic and pharmacokinetic changes that occur in pregnancy.
3. Assess hypertensive disorders of pregnancy and devise treatment plans throughout pregnancy.
4. Develop an appropriate medical regimen for peripartum cardiomyopathy.
5. Design safe and effective anticoagulant regimens during pregnancy.
6. Develop pharmacotherapy to manage acute arrhythmia in the pregnant patient.

Daniel M. Riche: Consultancies (Novo Nordisk; Merck; AstraZeneca); Royalties (McGraw-Hill)
Jessica Bente: Grants (New Jersey Society of Health-System Pharmacists)
Nothing to disclose: Glenn Herrington, Elisabeth M. Wang, Eman Elsayed Younis

Jessie Dunne: Consultancies (Pulmonary Hypertension Association)
Nothing to disclose: Lindsey Federle, Leslie Wooten

Universal Activity Number: 0217-0000-22-086-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-22-087-H01-P
1.5 CPE contact hours
Application-Based Activity

This feature was developed from an interactive case presented in PSAP 2021 Book 3 (Chronic Conditions and Public Health).

• Interactive Case: Click here to access the interactive case.

This feature was developed from an interactive case presented in PSAP 2021 Book 3 (Chronic Conditions and Public Health).

• Interactive case: Click here to access the interactive case.

Author: Timothy D. Gladwell, Pharm.D., BCPS, BCACP
Reviewed by: Rebecca M. Law, Pharm.D.; Ann Nadrash, Pharm.D., BCPS; and Kimberly N. Blanton, Pharm.D., BCPS

Authors: Mary Barna Bridgeman, Pharm.D., FCCP, FNAP, BCPS, BCGP; and Luigi Brunetti, Pharm.D., MPH, BCPS, BCGP
Reviewed by: Kathy Eroschenko, Pharm.D.; Tara B. Vlasimsky, Pharm.D., BCPS, BCACP; and Daniel Majerczyk, Pharm.D., BCPS, BC-ADM, CACP

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with chronic disease and need for public health–related services.

Learning Objectives

1. Apply data from contemporary studies of epidemiology and pathophysiology to the assessment and treatment of patients with psoriasis.
2. Evaluate the severity of a patient’s psoriasis in order to justify a general treatment approach.
3. Develop an evidence-based treatment regimen to manage the clinical manifestations of a patient’s psoriasis.
4. Develop a plan for screening and managing psoriasis-related comorbidities and adverse effects of therapy according to current guidelines.
5. Design a treatment plan to manage special populations of patients with psoriasis.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with chronic disease and need for public health–related services.

Learning Objectives

1. Evaluate combination pharmacologic agents for the treatment of benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS), including adverse effects and monitoring.
2. Design an appropriate treatment approach for a patient with BPH/LUTS, including the role of combination therapy.

Rebecca Law: Royalties (McGraw-Hill, Springer Nature); Consultancies (Memorial University of Newfoundland); Honoraria (Memorial University of Newfoundland Faculty of Medicine
Kimberly N. Blanton; Timothy D. Gladwell; Ann Nadrash: Nothing to disclose

Mary Barna Bridgeman: Grants (Merck and Co.); Honoraria (AstraZeneca)
Luigi Brunetti: Consultancies (Tabula Rasa Healthcare, Horizon Blue Cross Blue Shield of New Jersey); Grants (Merck and Co., CSL Behring, Innovative Research)
Kathy Eroschenko: Grants (Idaho Office of Drug Policy)
Tara B. Vlasimsky: Stock Ownership (Imidex)
Daniel Majerczyk: Nothing to disclose

Universal Activity Number: 0217-0000-22-072-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-22-073-H04-P
1.5 CPE contact hours
Application-Based Activity

This feature was developed from an interactive case presented in PSAP 2021 Book 2 (Neurology and Psychiatry).

• Interactive Case: Click here to access the interactive case.

This feature was developed from an interactive case appearing in PSAP 2021 Book 2 (Neurology and Psychiatry).

• Interactive case: Click here to access the interactive case.

Author: Barbara Farrell, Pharm.D., ACPR, FCSHP
Reviewed by: Kristina M. Ward, Pharm.D., BCPS, BCPP; and Amanda McFee Winans, Pharm.D., BCPS, CACP

Author: David R. Foster, Pharm.D., FCCP; and Kevin M. Sowinski, Pharm.D., FCCP
Reviewed by: Curtis E. Haas, Pharm.D., FCCP; Micheline Goldwire, Pharm.D., MS, BS, BCPS; and Tanvi Patil, Pharm.D., BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with psychiatric and neurologic diseases.

Learning Objectives

1. Evaluate patients with insomnia for appropriateness of benzodiazepine receptor agonist (BZRA) deprescribing.
2. Apply patient engagement and shared decision-making approaches to facilitate BZRA deprescribing.
3. Design, implement, and monitor BZRA deprescribing plans for patients with insomnia.
4. Develop nonpharmacologic support plans for insomnia during and after BZRA deprescribing.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists who regularly design research studies or who are called upon to interpret the results of published data.

Learning Objectives

1. Evaluate appropriate clinical trial study design elements, including considerations of randomization and blinding.
2. Distinguish clinical trial design features including subgroup analyses, composite endpoints, early cessation, surrogate endpoints, non-randomized designs, and internal/external validity.
3. Assess event rates or risks observed in clinical trials.
4. Compute and evaluate absolute risk reduction, relative risk reduction and number needed to treat.
5. Identify decision errors (Type I, Type II error) encountered in clinical trials.
6. Justify the use of components necessary for sample size estimation in clinical trials.

Barbara Farrell: Grants (CABHI Spark Program; Government of Ontario through the Bruyere Centre for Learning, Research and Innovation in Long-term Care; Canadian Institutes of Health Research; Canadian Foundation for Healthcare Improvement and Canadian Frailty Network; The Ottawa Hospital Academic Medical Organization); Honoraria (Pacific Psychopharmacology Conference, Canada; Ontario Long-Term Care Clinicians, Canada; The University of Bath; ASHP; National University Hospital, Singapore; Peterborough Regional Health Centre; Copenhagen University Hospital Bispebjerg; Canadian Foundation for Healthcare Improvement; Canadian Society of Hospital Pharmacists)
Kristina M. Ward: Honoraria (College of Psychiatric and Neurologic Pharmacists; ASHP)
Amanda McFee Winans: Nothing to disclose

David R. Foster, Kevin M. Sowinski, and Tanvi Patil: Nothing to disclose
Curtis E. Haas: Consultancies (Vizient, KJT Consulting, Pharmacy Times)
Micheline Goldwire: Honoraria (Alliance for Pharmacy Compounding)

Universal Activity Number: 0217-0000-22-017-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-22-018-H04-P
1.5 CPE contact hours
Application-Based Activity

This feature was developed from an interactive case presented in PSAP 2021 Book 2 (Neurology and Psychiatry).

• Interactive Case: Click here to access the interactive case.

This feature was developed from an interactive case appearing in PSAP 2021 Book 1 (Infectious Diseases).

• Interactive case: Click here to access the interactive case.

Author: Kristen N. Gardner, Pharm.D., BCPP
Reviewed by: Roger W. Sommi, Pharm.D., FCCP, BCPP; Jennifer Bean, Pharm.D., BCPS, BCPP; and Lauren Schmidt, Pharm.D., BCPS

Author: Daniel R. Touchette, Pharm.D., M.A., FCCP; and Ryan Rodriguez, Pharm.D., BCPS
Reviewed by: Kevin Sowinski, Pharm.D., FCCP; Haley Ilcewicz, Pharm.D., BCPS; and Kerry Anne Rambaran, Pharm.D., BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced level clinical pharmacists encountering patients with psychiatric and neurologic diseases.

Learning Objectives

1. Evaluate differential risk of antipsychotic adverse effects and monitor accordingly.
2. Design a pharmacotherapeutic plan for a patient with antipsychotic-related metabolic syndrome.
3. Assess patients for common antipsychotic-related movement disorders.
4. Distinguish among pharmacotherapy options for tardive dyskinesia management.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists who regularly design research studies or who are called upon to interpret the results of published data.

Learning Objectives

1. Assess data used in survival analysis, including censored observations.
2. Interpret results from Kaplan-Meier curves, Cox proportional hazards models, and log-rank tests.
3. Determine the most appropriate survival analysis to perform, including when the assumption of proportional hazards is not met.

Kristen N. Gardner: Consultancies (Biostrategies)
Roger W. Sommi: Grants (Alkermes; Neurocrine; Boeringer Ingelheim); Honoraria (Alkermes; Intracellular Therapies; Sunovion)
Jennifer Bean, Lauren J. Schmidt: Nothing to disclose

Touchette (Consultancies: Institute for Clinical and Economic Review, Monument Analytics); Grants Institute for Clinical and Economic Review)
Curtis E. Haas: Consultancies (Vizient, KJT Consulting, Pharmacy Times)
Ryan Rodriguez: Honoraria (ACCP)
Haley Ilcewicz, Kerry Anne Rambaran: Nothing to disclose

Universal Activity Number: 0217-0000-21-267-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-21-268-H04-P
1.5 CPE contact hours
Application-Based Activity

This feature was developed from an interactive case appearing in PSAP 2021 Book 1 (Infectious Diseases).

• Interactive Case: Click here to begin this activity.

This feature was developed from an interactive case appearing in PSAP 2020 Book 3 (Hematology and Oncology).

• Interactive case: Click here to begin this activity.

Author: Heather Gibson, Pharm.D., BCIDP, BCPS is and Antimicrobial Stewardship Pharmacist for the Departments of Infection Control and Pharmacy, FirstHealth of the Carolinas Moore Regional Hospital, Pinehurst, North Carolina.
Reviewed by: Dana R. Bowers, Pharm.D., BCPS-AQ ID, BCIDP; and Samantha Yeates, Pharm.D., BCPS

Author: Curtis E. Haas, Pharm.D., FCCP, is Director of Pharmacy at the University of Rochester Medical Center in Rochester, New York.
Reviewed by: Daniel R. Touchette, Pharm.D., MA, FCCP; and Lan N. Bui, Pharm.D., MPH, BCPS

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists encountering patients with infectious diseases.

Learning Objectives

1. Assess the use of antibiotic optimization strategies as antimicrobial stewardship initiatives.
2. Analyze the data supporting the use of each optimization strategy to determine its clinical effectiveness and place in practice.
3. Evaluate patient profiles to determine which optimization strategies are appropriate to use to improve patient outcomes.

Target audience for this application-based activity:
Pharmacotherapy specialists and advanced-level clinical pharmacists who regularly design research studies or who are called upon to interpret the results of published data.

Learning Objectives

1. Distinguish regression from correlation models and how each is applied to the analysis and understanding of clinical data.
2. Evaluate the results of common regression and correlation models, and how these results can be used in the interpretation and application of clinical data.
3. Apply the results of a multiple regression model in the analysis of clinical trial data, including how independent variables are best selected for a multiple regression model.
4. Evaluate results from a non-parametric Spearman Rank Order Correlation model.
5. Justify the use of common generalized linear models in regression analysis of different response variable types.

Heather Gibson, Dana Bowers, Samantha Yeates: Nothing to disclose

Curtis E. Haas: Consultancies (Vizient, KJT Consulting, Pharmacy Times)
Daniel R. Touchette (Consultancies: Institute for Clinical and Economic Review, Monument Analytics); (Grants Institute for Clinical and Economic Review)
Lan Bui: Nothing to disclose

Universal Activity Number: 0217-0000-21-233-H01-P
1.5 CPE contact hours
Application-Based Activity

Universal Activity Number: 0217-0000-21-234-H04-P
1.5 CPE contact hours
Application-Based Activity